DeepMed Research

JANSSEN RESEARCH & DEVELOPMENT, LLC

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis

Phase 3

Recruiting

Conditions: Plaque Psoriasis

Interventions: Drug: JNJ-77242113
Drug: Matching Placebo to Ustekinumab
Drug: Matching Placebo to JNJ-77242113
Drug: Ustekinumab

First Posted Date: 2025-04-18

Last Posted Date: 2025-05-23

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 675

Registration Number: NCT06934226

Locations: 🇵🇹
Hosp. Cuf Descobertas, Lisboa, Portugal
🇵🇹
Ulssa Hosp. Santo Antonio, Porto, Portugal
🇪🇸
Hosp. Univ. San Cecilio, Granada, Spain

and more 112 locations

A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer

Phase 3

Not yet recruiting

Conditions: Non-Muscle Invasive Bladder Neoplasms

Interventions: Drug: TAR-210
Drug: Mitomycin C
Drug: Gemcitabine

First Posted Date: 2025-04-09

Last Posted Date: 2025-05-23

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 220

Registration Number: NCT06919965

A Study of JNJ-95475939 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (AD)

Phase 2

Recruiting

Conditions: Dermatitis, Atopic

Interventions: Drug: Dupilumab
Drug: JNJ-95475939
Drug: Placebo

First Posted Date: 2025-03-18

Last Posted Date: 2025-05-23

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 240

Registration Number: NCT06881251

Locations: 🇺🇸
First OC Dermatology, Fountain Valley, California, United States
🇺🇸
Hamilton Research LLC, Alpharetta, Georgia, United States
🇺🇸
Dawes Fretzin Clinical Research Group LLC, Indianapolis, Indiana, United States

and more 46 locations

A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naïve Participants With Active Psoriatic Arthritis

Phase 3

Recruiting

Conditions: Arthritis, Psoriatic

Interventions: Drug: Icotrokinra
Drug: Placebo
Drug: Active reference comparator

First Posted Date: 2025-03-17

Last Posted Date: 2025-05-23

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 540

Registration Number: NCT06878404

Locations: 🇵🇱
DermMedica Sp z o o, Wroclaw, Poland
🇺🇸
Arthritis and Rheumatism Associates ARA Jonesboro, Jonesboro, Arkansas, United States
🇦🇷
Consultora Integral de Salud SRL, Cordoba, Argentina

and more 124 locations

Pre-Approval Expanded Access Study for TAR-200 Treating Physician Use

Conditions: Non-Muscle Invasive Bladder Neoplasms

First Posted Date: 2025-03-14

Last Posted Date: 2025-05-28

Lead Sponsor: Janssen Research & Development, LLC

Registration Number: NCT06877676

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Acute Myeloid Leukemia (AML)

Phase 3

Not yet recruiting

Conditions: Leukemia, Myeloid, Acute

Interventions: Drug: Bleximenib
Drug: Venetoclax (VEN)
Drug: Azacitidine (AZA)
Drug: Placebo

First Posted Date: 2025-02-28

Last Posted Date: 2025-05-04

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 600

Registration Number: NCT06852222

Locations: 🇮🇱
Hadassah University Hospita Ein Kerem, Jerusalem, Israel

A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced Participants With Active Psoriatic Arthritis

Phase 3

Recruiting

Conditions: Arthritis, Psoriatic

Interventions: Drug: Icotrokinra
Drug: Placebo

First Posted Date: 2025-02-04

Last Posted Date: 2025-05-23

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 750

Registration Number: NCT06807424

Locations: 🇪🇸
Hosp. Virgen Del Rocio, Sevilla, Spain
🇨🇳
National Taiwan University Hospital Hsin Chu Branch, Hsin Chu, Taiwan
🇩🇰
Regionshospitalet Godstrup, Herning, Denmark

and more 135 locations

A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring

Phase 1

Conditions: Leukemia, Myeloid, Acute
Leukemia, Lymphocytic, Chronic, B-Cell
Lymphoma, Non-Hodgkin
Myelodysplastic Syndromes
Neoplasms
Solid Tumor, Adult
Metastatic Castration-resistant Prostate Cancer (mCRPC)

Interventions: Drug: JNJ-75348780
Drug: JNJ-67856633
Drug: JNJ-54179060
Drug: JNJ-64264681
Drug: JNJ-74856665
Drug: JNJ-70218902
Drug: JNJ-64619178

First Posted Date: 2025-01-23

Last Posted Date: 2025-05-28

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 80

Registration Number: NCT06788509

Locations: 🇮🇱
Rambam Medical Center, Haifa, Israel
🇰🇷
Severance Hospital Yonsei University Health System, Seoul, Korea, Republic of
🇬🇧
University Hospitals Of Leicester Nhs Trust, Leicester, United Kingdom

and more 17 locations

A Study to Explore the Efficacy of JNJ-89495120 in the Treatment of Major Depressive Disorder

Phase 2

Recruiting

Conditions: Depressive Disorder, Major

Interventions: Drug: JNJ-89495120
Drug: Placebo

First Posted Date: 2025-01-20

Last Posted Date: 2025-05-23

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 124

Registration Number: NCT06785012

Locations: 🇺🇸
Interventional Psychiatry of Tampa Bay, Tampa, Florida, United States
🇺🇸
Wake Research PRI Encino, Encino, California, United States
🇺🇸
WR-Newport Beach, Newport Beach, California, United States

and more 27 locations

A Study of JNJ-79635322 in Combination With Daratumumab or Pomalidomide for Multiple Myeloma

Phase 1

Recruiting

Conditions: Multiple Myeloma

Interventions: Drug: JNJ-79635322
Drug: Daratumumab
Drug: Pomalidomide

First Posted Date: 2025-01-10

Last Posted Date: 2025-04-25

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 100

Registration Number: NCT06768489

Locations: 🇦🇺
Monash Medical Centre, Clayton, Australia
🇳🇱
VU Medisch Centrum, Amsterdam, Netherlands
🇳🇱
Universitair Medisch Centrum Groningen, Groningen, Netherlands

and more 10 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy